At MD&M East Several suppliers agreed that the Affordable Care Act doesn't really affect them much, but one said if patient choice gets hampered because of lower reimbursement for some...
Demand for quality healthcare from a growing middle class and aging population will continue to create opportunities for medtech entrepreneurs.
Yale's review of Medtronic's controversial bone growth product Infuse is mixed but the negatives are not high enough that it will be pulled from the market.